A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma

Inclusion Criteria: * Histologic or cytologic diagnosis of adenocarcinoma of the pancreas. * Resectable primary tumor of the head, body or tail of the pancreas defined as a visible mass in the pancreas and: * No extrapancreatic disease * A patent superior mesenteric (SMV)- portal vein (PV) confluence (assuming the technical ability to resect and reconstruct this venous confluence if needed) * A definable tissue plane between the tumor and regional arterial structures including the celiac axis, common hepatic artery, and SMA. * Confirmation of resectability by surgical oncology consultation. * Presentation at a multidisciplinary conference at either University of Chicago or NorthShore University * No previous therapy for pancreatic cancer * Short removable metal stents rather than plastic stents are preferred but not required for palliation of initial obstructive jaundice * Karnofsky performance status 80 or better * Age \> 21 years * No currently active second malignancy * No CVA within 6 months, no MI within 6 months * The effects of mFOLFIRINOX on the developing human fetus are unknown. For this reason and because chemotherapy agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregna…